Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

JULIET trial update on CAR T in DLBCL

Maziarz RT et al. N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980

Key clinical point: Chimeric antigen receptor T-cell therapy produced durable responses in patients with heavily pretreated diffuse large B-cell lymphoma.

Major finding: The best overall response rate, the primary endpoint, was 52%, comprising 40% complete responses and 12% partial responses.

Study details: A single-arm, open-label study of tisagenlecleucel in adults with relapsed or refractory diffuse large B-cell lymphoma.

Disclosures: The JULIET trial is supported by Novartis. Dr. Maziarz reported personal fees from Incyte, Kite Therapeutics, and Athersys.

Read the article here.

Citation:

Maziarz RT et al. N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980.

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6